Diabetes News: Retatrutide for Diabetes and Weight Loss

This content is not subject to review by Daily Kos staff prior to publication.

Facebook Share on Bluesky (Opens in new window)Bluesky Share on X (Opens in new window)X Share using Native toolsShareCopied to clipboard Save 0 Comments Add Daily Kos to Google Wikipedia Some of my friends say that they love living in the future, and here it is again. We have several diabetes medicines that turned out to be good for weight loss and other medical issues, but this new one from Eli Lilly promises to outdo the earlier ones, with three modes of biochemical action. It isn’t approved yet, and there are severe warnings about jumping the gun to buy retatrutide, or something packaged as retatrutide, on the black market. Yes, I understand the desperation of those who have some disorder or disease with no available treatment. We used to have panic buying of “laetrile”, which was pure quackery, and all sorts of outright conspiracy theories about HIV/AIDS. There is certainly quackery surrounding diabetes and weight loss and neuropathy today.

TRIUMPH-2 findings suggest that retatrutide might advance the treatment of people with obesity and type 2 diabetes, showing bodyweight reduction alongside improvements in glycaemic control and cardiometabolic risk factors. Read more: spkl.io/633207VNIE #EASD2026

Retatrutide is an experimental drug[1] for obesity developed by the American pharmaceutical company Eli Lilly and Company. It is a triple hormone receptor agonist on the GLP-1, GIP, and glucagon receptors.[2][3][4]

GLP-1 receptors improve insulin sensitivity and increase satiety. Retatrutide has shown to increase insulin secretion. Furthermore, agonism of the glucagon receptor increases energy expenditure and promotes fat loss and metabolic activity. With current research, activation of these receptors has overall reduced caloric intake and increased energy expenditure, successfully leading to higher weight loss compared to alternative treatments.[2]

Medical Xpress: Triple-action drug retatrutide delivers major weight loss for people with diabetes, Phase III trial finds

A recent Phase III clinical trial, TRIUMPH-2, evaluated the efficacy and safety of retatrutide, a triple receptor agonist and experimental once-weekly injection being developed to treat obesity and type 2 diabetes. What sets it apart from drugs such as semaglutide (Wegovy), which targets one hormone, and tirzepatide (Zepbound), which targets two, is its ability to activate three hormone receptors at once.

Developed by Eli Lilly, retatrutide mimics GLP-1, which lowers blood sugar and promotes fullness, and GIP, which enhances the body’s insulin response and helps reduce body weight alongside GLP-1. It also activates glucagon receptors, adding a third mechanism that increases energy expenditure and metabolic activity, helping the body burn more energy.

After 80 weeks of once-weekly injections, 1,152 adults living with both obesity and type 2 diabetes saw major changes on the scale. Those on the highest dose lost an average of 18.8% of their body weight, roughly 20.7 kg (about 45.5 pounds), compared with 5.1% in the placebo group. The loss was even bigger for those who started with a BMI of 35 or higher, who lost an average of 21.9% of their body weight on the 12 mg dose.

Sounds right for me. I need to lose a third of my body mass.

You can find out whether Lilly has a clinical trial that you can join. The site showed my one trial for a different drug that is too far for me to travel, but I signed up for e-mails to tell me of others.

FDA approval is expected next year, but too many people are too impatient.

Retatrutide is in the final phase of clinical trials and isn't expected to be submitted for FDA approval until next year. That hasn't stopped more than a dozen other medical facilities in Georgia from circumventing the FDA process by selling it.bit.ly/3VN1enW

A foreign influence operation tried to use Daily Kos to spread propaganda, but we caught it. Catching them takes constant work. Bots, fake accounts, and disinformation campaigns hit our site regularly and our team finds them and shuts them down. We don't have a billionaire backer or a paywall to pay for that work, we rely on readers like you.

Your contribution keeps independent, progressive media running and gives the truth a fighting chance. Give $5 today.

Sign up for our daily top stories newsletter so you don't miss how it's being used—and what comes next.

This content was created by a Daily Kos Community member.

Recommending and sharing stories helps us decide which stories are most important to show our readers.

Facebook Share on Bluesky (Opens in new window)Bluesky Share on X (Opens in new window)X Share using Native toolsShareCopied to clipboard Comments didn't load?

It could be because of network issues or a problem with our commenting provider, or your browser or an extension may be blocking them. This can happen with Firefox Strict mode, uBlock Origin, Brave, or ad blockers. Try reloading the page, disabling your ad blocker for this site, or switching Firefox's Enhanced Tracking Protection to Standard mode.

Sign up for our daily top stories newsletter so you don't miss how it's being used—and what comes next.